Summary | |
---|---|
Symbol | TMPO |
Name | thymopoietin |
Aliases | LEMD4; LEM domain containing 4; CMD1T; PRO0868; TP alpha; TP beta/gamma; lamina-associated polypeptide 2; th ...... |
Chromosomal Location | 12q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Nucleus. Chromosome. Note=Expressed diffusely throughout the nucleus. |
Domain |
PF11560 Lamina-associated polypeptide 2 alpha PF03020 LEM domain PF08198 Thymopoietin protein |
Function |
May be involved in the structural organization of the nucleus and in the post-mitotic nuclear assembly. Plays an important role, together with LMNA, in the nuclear anchorage of RB1.; FUNCTION: TP and TP5 may play a role in T-cell development and function. TP5 is an immunomodulating pentapeptide. |
Biological Process | - |
Molecular Function |
GO:0005521 lamin binding GO:0045296 cadherin binding GO:0050839 cell adhesion molecule binding GO:0098631 protein binding involved in cell adhesion GO:0098632 protein binding involved in cell-cell adhesion GO:0098641 cadherin binding involved in cell-cell adhesion |
Cellular Component |
GO:0000785 chromatin GO:0005635 nuclear envelope GO:0005637 nuclear inner membrane GO:0005913 cell-cell adherens junction GO:0031965 nuclear membrane |
KEGG | - |
Reactome |
R-HSA-1640170: Cell Cycle R-HSA-69278: Cell Cycle, Mitotic R-HSA-2993913: Clearance of Nuclear Envelope Membranes from Chromatin R-HSA-4419969: Depolymerisation of the Nuclear Lamina R-HSA-2995383: Initiation of Nuclear Envelope Reformation R-HSA-68886: M Phase R-HSA-68882: Mitotic Anaphase R-HSA-2555396: Mitotic Metaphase and Anaphase R-HSA-68875: Mitotic Prophase R-HSA-2980766: Nuclear Envelope Breakdown R-HSA-2995410: Nuclear Envelope Reassembly |
Summary | |
---|---|
Symbol | TMPO |
Name | thymopoietin |
Aliases | LEMD4; LEM domain containing 4; CMD1T; PRO0868; TP alpha; TP beta/gamma; lamina-associated polypeptide 2; th ...... |
Chromosomal Location | 12q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between TMPO and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | TMPO |
Name | thymopoietin |
Aliases | LEMD4; LEM domain containing 4; CMD1T; PRO0868; TP alpha; TP beta/gamma; lamina-associated polypeptide 2; th ...... |
Chromosomal Location | 12q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of TMPO in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | TMPO |
Name | thymopoietin |
Aliases | LEMD4; LEM domain containing 4; CMD1T; PRO0868; TP alpha; TP beta/gamma; lamina-associated polypeptide 2; th ...... |
Chromosomal Location | 12q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of TMPO in various data sets.
|
Points in the above scatter plot represent the mutation difference of TMPO in various data sets.
|
Summary | |
---|---|
Symbol | TMPO |
Name | thymopoietin |
Aliases | LEMD4; LEM domain containing 4; CMD1T; PRO0868; TP alpha; TP beta/gamma; lamina-associated polypeptide 2; th ...... |
Chromosomal Location | 12q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TMPO. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | TMPO |
Name | thymopoietin |
Aliases | LEMD4; LEM domain containing 4; CMD1T; PRO0868; TP alpha; TP beta/gamma; lamina-associated polypeptide 2; th ...... |
Chromosomal Location | 12q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TMPO. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TMPO. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | TMPO |
Name | thymopoietin |
Aliases | LEMD4; LEM domain containing 4; CMD1T; PRO0868; TP alpha; TP beta/gamma; lamina-associated polypeptide 2; th ...... |
Chromosomal Location | 12q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TMPO. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | TMPO |
Name | thymopoietin |
Aliases | LEMD4; LEM domain containing 4; CMD1T; PRO0868; TP alpha; TP beta/gamma; lamina-associated polypeptide 2; th ...... |
Chromosomal Location | 12q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of TMPO expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | TMPO |
Name | thymopoietin |
Aliases | LEMD4; LEM domain containing 4; CMD1T; PRO0868; TP alpha; TP beta/gamma; lamina-associated polypeptide 2; th ...... |
Chromosomal Location | 12q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between TMPO and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | TMPO |
Name | thymopoietin |
Aliases | LEMD4; LEM domain containing 4; CMD1T; PRO0868; TP alpha; TP beta/gamma; lamina-associated polypeptide 2; th ...... |
Chromosomal Location | 12q22 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting TMPO collected from DrugBank database. |
There is no record. |